

616.3:612.017.2

1, 2

2

(VEGF)

[1,2].

VCAM-1 ICAM-1), (IL-1, TNF $\alpha$  IFN $\gamma$ ). ( -1 NF- ), ( -

(mtDNA). P2Y<sub>2</sub>R, mtROS-mtDNA (mtROS) IL-1 $\beta$  [3].

ERK5 20 (TNFAIP3) NF- [4-6].

(NO, (

NO [7-9].

[10-11].

→ (NOS), (NOS-1) (NO): (eNOS), (NOS-3) (nNOS) (iNOS).

(NOS-2)

NOS-3 -

( 50-100 )

-3-

NOS

NO,

L-

- G-

Cavl

NADPH

L-

NO

eNOS. NO

NO

[13-15].

2 :

NO

( )

(

-6-10

NO

500

NO

3

( NO

1,7

4

/

1

).

NO

); NO

: S-

S-

( S-

(RSNO).

NO

.) [14-16].

( )

G,

2+

2"

(MLCK)

3

( [15, 17].

G),

NO

[18, 19].

NO

NO

NO

[20].

(ECLIP)

[21].

(LIP),

(CLIP)

[22].

-3-

(1 3)

(MLCK).

(MLC),

1.

(  
(VDCC) -  
→

Na<sup>+</sup>, Ca<sup>2+</sup>-

—\*

2+

VGCC  
2+  
1000

2. NPY -

Y -

36

NPY-

( ) →

Gi-

MLCP (

MLCK —\*  
) MLCs ( (MHCs).

MLC

MLCK —\*  
( )

3.

—\*

Gq-

→

→

(PLC) —\*  
(1 3) DAG) →  
2+

4.

1 3

—\*

PLC —

→

I —\*

1 3

DAG —

:

Gq —\*  
1 3

5.

→

[23].

[24].

(TPR).

TPR

[25].

[26].

1.

2+

2.

3.

G  
(MLC)

G ( - ) -

MLCK →»

MLCK →»•

MLC →

; 2)  
2+

SERCA ( 2+-

) →\*

( IP ),

D<sub>2</sub> ( DP- ),

2 ( ) ,

→ MLCK →\*

Gs-

→\*

( ) →

MLCK

VIP

( Gs- — ... ; 2) VIP →\*

): 1) VIP →  
VDCC →

( + 2+ ) →\*

→ VDCC →

2+ → ...

( P2Y ) →

Gq →

→\*

2+ →

L- ( Na<sup>+</sup>, K<sup>-</sup> -2 ? ) →

N0 → ...

Gi —

Na<sup>+</sup> →\*

→ + + Na<sup>+</sup>, K<sup>-</sup> →

2+ → ...

I<sub>2s</sub>

[27,28].

B-

[29].

, G-



1,

1

$O_2^-$

Src

- [36-38].

2"

(MLCP)

MLCP

Rho-

(ROCK)

RhoA,

-1

(MYPT1).

ROCK

Rho-

GPCR,

(RhoGEF).

NOX1-

NOX2-

JAK2 (

-2). RhoGEF

Src-

PYK2 (

(FAK)

$O_2^-$  (

NOX4)

-2,

(Poldip2). Poldip2 -

RhoA

[39, 40].

[35].

1) NOX1,2,4,5


G-

; 2) NOX1,2,5 -

; 3) NOX4 -

; 4) NOX4,5 -

; 5) NOX1,2,4,5 -



. 1.

(NOX),

[35].

, Aqu -

, GPCR -

G-

, RTK -

TNFR -

GPX -

, VSM -

, Cat -

, SOD -

, PRX -




Рис. 2. Окислительный стресс и пути развития артериальной гипертензии [35]. Символом SHR ; CIH -

NRTKs, FAK, Src, PYK2 JAK2, ( )

RhoA/ROCK. VSM NF-kB. (mean arterial pressure, )

20<sub>2</sub> « », [35]. NOX4, Nrf2.

NFE2L2. NRF2

Nrf2 Nrf2

1, -8- [54-57].

4, ONOO', eNOS NO- eNOS NO-

eNOS. Ang II eNOS 2,

20<sub>2</sub>

NO-

[46-49].

SERCA [50, 51].

[52, 53].

Nrf2-

[35].

[58-61].

- [1] . Mizuno Y., Jacob R.F., Mason R.P. Inflammation and the development of atherosclerosis // Journal of Atherosclerosis and Thrombosis. 2011. Vol.18 (5). P. 351-358.
- [2] . Rajendran P., Rengarajan T., Thangavel J., Nishigaki Y et al. The vascular endothelium and human diseases //Int. J. Biol. Sci. 2013. Vol. 9 (10). P. 1057-1069.
- [3] . Jin H., Ko Y.S., Park S.W., Kim H.J. P2Y<sub>2</sub>R activation by ATP induces LDL-mediated inflammasome activation through modulation of mitochondrial damage in human endothelial cells // Free Radical Biologie and Medicine. 2019. Vol. 136. P. 109-117.
- [4] . Roberts O.L., Holmes K, Müller J., Cross D.A., Cross M.J. ERK5 and the regulation of endothelial cell function // Biochemical Society Transactions. 2009. Vol. 37 (Pt 6). P. 1254-1259.



- [5] . Vanichkitrungruang S., Chuang C.Y., Hawkins J., Hammer A. et al. Oxidation of human plasma fibronectin by inflammatory oxidants perturbs endothelial cells function // *Free Radical Biology and Medicine*. 2019. Vol. 136. P. 118-134.
- [6] . Yu H., Kalogeris T., Korthis R.J. Reactive species-induced microvascular dysfunction in ischemia/reperfusion // *Free Radical Biology and Medicine*. 2019. Vol. 135. P. 182-197.
- [7] . Bauer V., Sotnikova R. Nitric oxide - the endothelium-derived relaxing factor and its role in endothelial functions // *General Physiol. Biophys.* 2010. Vol.29, No 4. P.319-340.
- [8] . Flammer A.J., Anderson T., Celermajer D.S., Creager M.A. et al. The assessment of endothelial function: from research into clinical practice // *Circulation*. 2012. Vol. 126 (6). P. 753-767.
- [9] . Münzel I., Sinning C, Post F., Warmholtz A., Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction // *Annals of Medicine*. 2008. Vol. 40 (3). P. 180-196.
- [10] .Lundberg J.O., Weitzberg E., Gladwin M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics // *Nature Reviews Drug Discovery*. 2008. Vol. 7 (2). P. 156-167.
- [11] J.Suschek C., Opiänder C. Nonenzymatic NO production in human skin: Effect of UVA on cutaneous NO stores // *Nitric Oxide*. 2010. Vol. 22 (2). P. 120-135.
- [12] Ignarro L.J. Nitric Oxide. A Novel Signal Transduction Mechanism For Transcellular Communication // *Hypertension*. 1990. Vol. 16 (5). P. 477-483.
- [13] .Osamai T, Fujiwara N, Saitoh M., Sasak S. et al. Relationship between salt intake, nitric oxide, and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease // *Blood Purification*. 2002. Vol. 20 (5). P.466-468.
- [14] .Davies, S.A., Stewart, E.J., Huesmaan, G.R and Skaer, N. J. Neuropeptide stimulation of the nitric oxide signalling pathway in *Drosophila melanogaster* Malpighian tubules // *Am. J. Physiol.* 1997. Vol. 273. R823-827.
- [15] / C.C. « » 2010. . 255-309.
- [16] .Shami P.J., Moore J.O., Gockerman J.P., Hathorn J.W. et al. (1995). Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells // *Leukemia Research*. 1995. Vol. 19 (8). P. 527-533.
- [17].Derbyshire E.R., Marietta M.A. Biochemistry of soluble guanylate cyclase / *Handb. Exp. Pharmacol. Handbook of Experimental Pharmacology*. 2009. Vol. 191. P. 17-31.
- [18] %].Pieper G.M., Clarke G.A., Gross G.J. Stimulatory and inhibitory action of nitric oxide donor agents vs. nitrovasodilators on reactive oxygen production by isolated polymorphonuclear leukocytes // *J. Pharmacol. Exp. Ther.* 1994. Vol. 269. P. 451-456.
- [19] . Singh A.K., Awasthi D., Dubey M., Nagarkoti S. et al. High oxidative stress adversely affects NfκB mediated induction of inducible nitric oxide synthase in human neutrophils: Implications in chronic myeloid leukemia // *Nitric Oxide*. 2016. Vol. 58. P. 28-41.
- [20] .Passos-Silva D.G., Verano-Braga T, Santos R. A. S. Angiotensin-(1-7): beyond the cardio-renal actions // *Clin Sci (Bond)*. 2013. Vol. 124 (7). P. 443-456.
- [21] J.Sahni S., Hickok J.R., Thomas D.D. Nitric oxide reduces oxidative stress in cancer cells by forming dinitrosyliron complexes // *Nitric Oxide*. 2018. Vol. 76. P. 37-44.
- [22] . Wilson D.P., Susnjar M., Riss E., Sutherland C. et al. Thromboxane A<sub>2</sub>-induced contraction of rat caudal arterial smooth muscle involves activation of Ca<sup>2+</sup> entry and Ca<sup>2+</sup> sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697 // *Biochem. J*. 2005. Vol. 389 (Pt 3). P. 763-774.
- [23] .Brozovich F.V., Nicholson C.J., Degen C.V., Cao Y.Z. et al. Mechanisms of vascular smooth muscle contraction and the basis for pharmacologic treatment of smooth muscle disorders // *Pharmacol. Rev*. 2016. Vol. 68. P. 476-532.
- [24] .Sato A., Terata K., Miura H., Toyama K. et al. Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease // *American Journal of Physiology. Heart and Circulatory Physiology*. 2005. Vol. 288 (4). H1633-1640.
- [25] .Charkoudian N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans // *Journal of Applied Physiology*. American Physiological Society. 2010. Vol. 109 (4). P. 1221-1228.
- [26] . Webb R.C. Smooth muscle contraction and relaxation // *Advances in Physiology Education*. 2003. Vol. 27 (1—4). P.201-2066.
- [27] .Marshall W.J., Bangert S.K. (Eds.) *Clinical Biochemistry. Metabolic and clinical aspects*. - N.-Y.: Churchill Livingstone, 1995. - 854 p.
- [28] .Kaplan L.A., Pesce A.J. (Eds.) *Clinical chemistry. Theory, analysis, and correlation*. Third edition. - N.-Y.:Mosby, 1996.- 1211 p.
- [29] . C.C. : iNOS : /
- [20] . : , 2019. - 216 .
- [20] .Tejero J, Shiva S., Gladwin M.T. Sources of vascular nitric oxide and reactive oxygen species and their regulation // *Physiol. Rev*. 2019. Vol. 99. P. 311-379.

- [31] J. Bedard, Krause. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology // *Physiol. Rev.* 2007. Vol. 87. P. 245-313.
- [32] Molier M.N., Rios N., Trujillo M., Radi R. et al. Detection and quantification of nitric oxide-derived oxidants in biological systems // *J. Biol. Chem.* 2019. Vol. 294 (40). P. 14776—14802.
- [33] Trevisani M., Siemens J., Materazzi S., Bautista D.M. et al. 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1 // *Proc. Natl. Acad. Sci. U. S. A.* 2007. Vol. 104. P. 13519-13524.
- [34] Monteiro H.P., Arai R.J., Travassos L.R. Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling// *Antioxidants Redox Signal.* 2008. Vol. 10. P. 843-889.
- [35] Knock G.A. NADPH oxidase in the vasculature: Expression, regulation and signaling pathways; role in normal cardiovascular physiology and its dysregulation in hypertension // *Free Radical Biology and Medicine.* 2019. Vol. 145. P. 385-427.
- [36] Ding Y, Winters A., Ding M., Graham S. et al. Reactive oxygen species-mediated TRPC6 protein activation in vascular myocytes, a mechanism for vasoconstrictor-regulated vascular tone // *J. Biol. Chem.* 2011. Vol. 286. P. 31799-31809.
- [37] Knock G.A., Snetkov V.A., Shaifta Y., Connolly M. et al. Superoxide constricts rat pulmonary arteries via Rho-kinase-mediated Ca<sup>2+</sup> sensitization // *Free Radic. Biol. Med.* 2009. Vol. 46. P. 633-642.
- [38] Amberg G.C., Earley S., Glapa S.A. Focal regulation of arterial L-type calcium channels by reactive oxygen species // *Circ. Res.* 2010. Vol. 107. P. 1002-1010.
- [39] Jin L., Ying Z., Webb R.C. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta // *Am. J. Physiol. Heart Circ. Physiol.* 2004. Vol. 287. P. H1495-H1500.
- [40] Hernandez M.S., Lassegue B., Helenski L.L., Adams J. et al. Polymerase delta-interacting protein 2 deficiency protects against blood-brain permeability in the ischemic brain // *Journal of Neuroinflammation*, 2018. Vol. 15 (1). P. 1-16.
- [41] Navia-Pelaez J.M., Campos-Mota G.P., de Souza J.C.A., Aguilera E.C. et al. NOS uncoupling by oxidized LDL: Implications in atherosclerosis // *Free Radical and Medicine.* 2017. Vol. 113. P. 335-336.
- [42] Liao Y., Gou L., Chen L., Zhong X. et al. NADPH oxidase 4 and endothelial nitric oxide synthase contribute to endothelial dysfunction mediated by histone methylations in metabolic memory // *Free Radical Biology and Medicine.* 2018. Vol. 115. P. 383-394.
- [43] Lee H.-Y., Zeeshan H.M.A., Kim H.-R., Chae H.-J. Nox4 regulates the eNOS uncoupling process in aging endothelial cells // *Free Radical Biology and Medicine.* 2017. Vol. 113. P. 26-35.
- [44] H.M. al-  
NO-  
2013. 99. 7. 859-868.
- [45] // -  
2020.
- [46] Camargo L.L., Harvey, Rios F.J., Tsiropoulou S. et al. Vascular NOX (NADPH oxidase) compartmentalization, protein hyperoxidation, and endoplasmic reticulum stress response in hypertension // *Hypertension.* 2018. Vol. 72. P. 235-246.
- [47] Zhang X, Yang J., Yu X, Cheng S. et al. Angiotensin II-induced early and late inflammatory responses through NOXs and pathways // *Inflammation.* 2017. Vol. 40. 154-165.
- [48] K.L., Gao L., Cai H. Differential Roles of Protein Complexes NOX1-NOXO1 and NOX2-p47phox in Mediating Endothelial Redox Responses to Oscillatory and Unidirectional Laminar Shear Stress // *J. Biol. Chem.* 2016. Vol. 291. P. 8653-8662.
- [49] Masi S., Uliana M., Virdis A. Angiotensin II and vascular damage in hypertension: Role of oxidative stress and sympathetic activation // *Vase. Pharmacol.* 2019. Vol. 115. P. 13-17.
- [50] Massaro M., Scoditti E., Carluccio M.A., De C.R. Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies? // *Vase. Pharmacol.* 2019. Vol. 116. P. 45-50.
- [51] Montezano A.C., Dulak-Lis M., Tsiropoulou S., Harvey A. et al. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies // *Can. J. Cardiol.* 2015. Vol. 31. P. 631-641.
- [52] Do Vale G.T., Tirapelli C.R. Are reactive oxygen species important mediators of vascular dysfunction? // *Curr. Hypertens. Rev.* 2019, <https://doi.org/10.2174/1573402115666190416153638>.
- [53] Pinheiro L.C., Oliveira-Paula G.H. Sources and effects of oxidative stress in hypertension // *Curr. Hypertens. Rev.* 2019, <https://doi.org/10.2174/1573402115666190531071924>.
- [54] Zhang J., Chen J., Yang J., Xu C.W. et al. Resveratrol attenuates oxidative stress induced by balloon injury in the rat carotid artery through actions on the ERK1/2 and NF-kappa pathway // *Cell. Physiol. Biochem.* 2013. Vol. 31. P.230-241.
- [55] Cabal-Hierro L., Lazo P.S. Signal transduction by tumor necrosis factor receptors // *Cell. Signal.* 2012. Vol. 24. P. 1297-1305.

- [58] . Yamamoto I, Suzuki , Kobayashi A., Wakabayashi J. et al. Physiological significance of reactive cysteine residues of Keap1 in determining NrB activity // Mol. Cell. Biol. 2008. Vol. 28. P. 2758-2770.
- [59] . Guo Y., Yu S., Zhang C., Kong A.N. Epigenetic regulation of Keap1-Nrf2 signaling //Free Radical Biology and Medicine. 2015. Vol. 88 (PtB). P. 337-349.
- [60] .Green L.C., de Luzuriaga K. Ruiz, Wagner D.A., Rand W., Istfan N., Young V.R., Tannenbaum S.R. Nitrate biosynthesis in man // Proc. Natl. Acad. Sei. U. S. A. 1981. Vol. 78 (12). P. 7764-7768.
- [61] .Ignarro L.J. Endothelium-derived nitric oxide: actions and properties // FASEB J. 1989. Vol. 3. P. 31-36.
- [62] .Waldman S.A., Murad F. Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system // J. Cardiovasc Pharmacol. 1988. Vol. 5 (12 Suppl). P. SI 15-SI 18.
- [63] .Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor//Nature. 1987. Vol. 327 (6122). P. 524-526.

: 20.04.2020 .

. . CHIRKIN<sup>1</sup>, N.M. JATSKOVSKAYA<sup>2</sup>

### **BLOOD VESSEL TONUS AND OXIDATIVE STRESS**

*<sup>1</sup>Vitebsk State University named after P.M. Masherov*

*<sup>2</sup>Vitebsk State Medical University*

#### **Summary**

In connection with the rapid development of knowledge about intercellular and intracellular signaling, the article summarizes modern ideas about the influence of oxidative stress molecules on vascular tone and the development of arterial hypertension. The state of redox systems and the bioavailability of nitric oxide are key factors controlling the effect of oxidative stress on vascular tone.

*Key words:* Oxidative stress, vascular tone, vasoconstriction, vasodilatation, nitric oxide.